Patent 11058725 was granted and assigned to Obsidian Therapeutics on July, 2021 by the United States Patent and Trademark Office.
The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.